Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, AA Thai, C Mascaux, S Couraud, R Veillon, M Van Den Heuvel, J Neal, N Peled, M Fruh, TL Ng, V Gounant, S Popat, J Diebold, J Sabari, VW Zhu Show all
Annals of Oncology | OXFORD UNIV PRESS | Published : 2019
BACKGROUND: Anti-PD1/PD-L1 directed immune-checkpoint-inhibitors (ICI) are widely used to treat patients with advanced non-small cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction. PATIENTS AND METHODS: We conducted a retrospective study for patients receiving ICI monotherapy for advanced NSCLC with at least one oncogenic driver alteration. Anonymized data were evaluated for clinicopathologic characteristics and outcomes for ICI therapy: best response (RECIST 1.1), progression-free survival (PFS) and overall survival (OS) from ICI init..View full abstract
This work was supported by public funding from Toulouse University Hospital (France) and Lucerne Cantonal Hospital (Switzerland). The research was carried out with no industry support and the paper was written by the authors without editorial assistance. No grant number is applicable.